유전자 편집 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Gene Editing Market size is expected to reach USD 29.51 Billion in 2034 from USD 7.80 Billion (2025) growing at a CAGR of 15.93% during 2026-2034.

The global gene editing market is witnessing rapid growth driven by advancements in genetic engineering and increasing demand for precision medicine. Technologies such as CRISPR are revolutionizing the ability to modify genes, offering potential treatments for genetic disorders and chronic diseases. The rising prevalence of genetic conditions and the growing focus on personalized healthcare are key factors driving market expansion. Additionally, increasing investments in biotechnology research are supporting innovation in gene editing technologies.

Key growth drivers include the expanding applications of gene editing in healthcare, agriculture, and research. The ability to develop targeted therapies and improve crop yields is attracting significant attention from various industries. Collaborations between biotechnology companies and research institutions are accelerating technological advancements. Furthermore, supportive government policies and funding for genetic research are contributing to market growth.

In the future, the gene editing market is expected to grow significantly with continuous advancements in technology and expanding application areas. The development of safer and more precise editing techniques will enhance clinical adoption. Emerging markets are likely to offer new growth opportunities due to increasing investments in biotechnology and healthcare infrastructure. Additionally, ongoing research will continue to unlock new possibilities in disease treatment and genetic modification.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

• CRISPR
• TALEN
• ZFN
• Others

By Application

• Biomedical
• Agriculture
• Industrial
• Others

By End-User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Clinical Research Organizations
• Others

COMPANIES PROFILED

• CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Sangamo Therapeutics, Beam Therapeutics, Precision BioSciences, Caribou Biosciences, Cellectis, Horizon Discovery Group, Bluebird Bio, Recombinetics, Inscripta, Synthego, Genscript Biotech, Origene Technologies
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GENE EDITING MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. CRISPR Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. TALEN Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. ZFN Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GENE EDITING MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Biomedical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Agriculture Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Industrial Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GENE EDITING MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Pharmaceutical and Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Clinical Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GENE EDITING MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Technology
  • 7.2.2 By Application
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Technology
  • 7.3.2 By Application
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Technology
  • 7.4.2 By Application
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Technology
  • 7.5.2 By Application
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Technology
  • 7.6.2 By Application
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GENE EDITING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 CRISPR Therapeutics
  • 9.2.2 Editas Medicine
  • 9.2.3 Intellia Therapeutics
  • 9.2.4 Sangamo Therapeutics
  • 9.2.5 Beam Therapeutics
  • 9.2.6 Precision BioSciences
  • 9.2.7 Caribou Biosciences
  • 9.2.8 Cellectis
  • 9.2.9 Horizon Discovery Group
  • 9.2.10 Bluebird Bio
  • 9.2.11 Recombinetics
  • 9.2.12 Inscripta
  • 9.2.13 Synthego
  • 9.2.14 Genscript Biotech
  • 9.2.15 Origene Technologies